Kazuya Machida, Editorial Board Member
University of Connecticut, USA
For over two decades, Kazuya Machida has studied protein phosphorylation, cell signaling, and conducted a number of translational research projects. He has sufficient experience and expertise in key research areas proposed in this application. During his PhD research training at Nagoya University School of Medicine, he studied cell transformation by constitutively activated tyrosine kinases and identified increased levels of tyrosine phosphorylation and dysregulated signaling in human tumors. He joined the Bruce Mayer laboratory at University of Connecticut Health Center in 2001 as a postdoctoral fellow and expanded his research interest to the phosphoproteomics area. In particular, he was interested in phosphotyrosine interacting domains, such as SH2 and PTB domains and their exploitation for phosphotyrosine profiling of human malignancies. Collaborating with Dr. Peter Nollau in Germany, they developed new qualitative and quantitative SH2 domain binding assays for global profiling of tyrosine phosphorylation (SH2 profiling). Professor Machida played a major role in the assay development, preparation of the entire set of human SH2 domain probes, and interrogation of SH2 binding sites in peptides, purified proteins, oncogene-transformed cells, growth factor-treated cells, and cancer specimens. Using the SH2 profiling methodologies and resources, he is continuing to conduct collaborative studies with Dr. Mayer's group addressing the role of time-resolved SH2–ligand interactions in downstream signaling. Independently, his group’s ongoing research is aiming at the discovery of new molecular markers for chronic leukemia based on the molecular signatures of SH2 binding sites. To pursue the translational research, he is leading a multidisciplinary study team consisting of physicians, nurses, research coordinators, bioinformatists, and molecular biologists. His specific expertise is reflected in the recent publication of a Method in Molecular Biology book, “SH2 Domains Methods and Protocols” from Springer on which he was a co-editor. Taken together, his expertise in tyrosine kinase and cell signaling, human cancer research, and SH2 domains provides a solid foundation to serve on the Editorial Board of Cell Communication and Signaling.